Potential Roles of Matrix Metalloproteinases in Malignant Mesothelioma by Ying, Shibo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Potential Roles of Matrix 
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Mesothelioma
Shibo Ying, Yanbin Wang and Lyuyang Lyu
Abstract
Malignant mesothelioma (MM) is a rare, aggressive, and highly lethal cancer 
that is primary induced by exposure to asbestos fibers. Matrix metalloproteinases 
(MMPs) are a family of zinc-dependent endopeptidases that are involved in metas-
tasis, and their overexpression correlates with tumor cell invasion and metastasis 
because they degrade the extracellular matrix (ECM) and process adhesion and 
cytoskeletal proteins, growth factors, chemokines, and cytokines. Recent evidence 
has shown that MMPs participate in MM progression, indicating that they are 
potential novel biomarkers and attractive targets for cancer therapy. In this chapter, 
we will describe MMPs in carcinogenic mechanisms based on in vivo and in vitro 
experimental evidence, outline the clinical findings, and speculate the possible roles 
of MMPs in MM.
Keywords: malignant mesothelioma, matrix metalloproteinases, 
mesothelial carcinogenesis, extracellular matrix, biomarker
1. Introduction
Malignant mesothelioma (MM) is a rare, aggressive cancer that originates 
from mesothelial tissue in the pleura, peritoneum, and pericardium; MM has been 
associated with asbestos exposure, especially in occupational settings [1]. In some 
countries, such as Turkey and Japan, MM is also due to environmental asbestos 
exposure, which affects people who live in the vicinity of natural asbestos mines 
or factories that use asbestos [2–4]. Mesothelioma is highly resistant to conven-
tional cancer therapies. MM patients usually have a poor prognosis, with a median 
survival of 12–18 months, due to the lack of effective treatments and difficulty in 
diagnosing this disease at the early stage [5–7]. In general, there are three main his-
tological subtypes of mesothelioma. The epithelioid and sarcomatoid subtypes are 
characterized by cuboid and fibroblastoid cells, respectively. The biphasic subtype 
contains a mixture of both cell types and confers the worst prognosis. The most 
widely used treatments for MM are surgery with or without adjuvant chemotherapy 
and/or radiotherapy [8]. The first-line treatment option for unresectable MM is 
chemotherapy with cisplatin plus pemetrexed [9, 10]. Nevertheless, MM may be 
resistant to these conventional therapeutic approaches, and palliative care strategies 
are controversial. Although crocidolite and/or chrysotile have not been used for 
more than 10 years in many developed and developing countries, high mortality 
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rates associated with mesothelioma persist since the clinical manifestations of MM 
are insidious and nonspecific. It is worth noting that MM has a long latency period 
(mean, 30–40 years) from the time of asbestos exposure to tumorigenesis [4, 11]. 
Thus, valuable biomarkers for the prediction or diagnosis of MM at early stages, 
prognostic markers, and novel therapeutic strategies are urgently needed.
Matrix metalloproteinases (MMPs, also known as matrixins) are a family of 
zinc-dependent endopeptidases that degrade all components of the extracellular 
matrix (ECM); thus, MMPs are involved in ECM remodeling. In addition to func-
tioning as the main ECM regulators, MMPs also modulate intra- and extracellular 
signaling pathways and networks through the proteolytic processing of various 
biomolecules. The first MMP was reported by Gross and Lapiere as a collagenase 
engaged in tail resorption during tadpole metamorphosis [12]. To date, 24 MMP 
genes, including a gene duplication, that encode 23 unique MMP proteins have been 
identified in humans [13, 14]. According to substrate specificity, sequence similar-
ity, and specific role, MMPs can be divided into eight main groups: (1) collagenases 
(MMP-1, MMP-8, and MMP-13), (2) matrilysins (MMP-7 and MMP-26), (3) 
metalloelastase (MMP-12), (4) stromelysins (MMP-3, MMP-10, and MMP-11), (5) 
gelatinases (MMP-2 and MMP-9); (6) enamelysin (MMP-20); (7) membrane-type 
MMPs (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, and MMP-25), and (8) 
others (MMP-19, MMP-21, MMP-23, MMP-27, and MMP-28) [13, 15]. Interestingly, 
the proteolytic activities of MMPs are precisely controlled by activation of their 
precursors and inhibition by endogenous inhibitors, α-macroglobulins, and tissue 
inhibitors of metalloproteinases [13]. Except for six membrane-associated MMPs, 
the other 17 MMPs are soluble secreted enzymes [16]. In addition, growth factors, 
chemokines, and cytokines modulate the expression of MMPs through various 
pathways to affect ECM degradation and, in turn, influence growth factors, which 
ultimately affect cancer cell migration and invasion [17, 18].
Of note, MMPs are expressed in various cancer tissues, and their expression 
levels are closely associated with the properties of invasive growth and metastasis 
[15]. Accumulating evidence suggests that ECM degradation by MMPs at the cell 
surface enhances tumor growth, invasion, and metastasis through the proteolytic 
degradation of ECM, altered cell-cell, and cell-ECM interactions and effects on cell 
migration and angiogenesis [17, 19]. More recently, the roles of different MMPs have 
become increasingly studied in the field of MM research. Experimental evidence 
indicates that MMP-1, MMP-2, and MMP-9 are involved in mesothelial carcinogen-
esis. Several MMPs, such as MMP-7, MMP-14, and MMP-9, are potential biomarkers 
for MM. In the following sections, we will describe the roles of MMPs in carcino-
genic mechanisms based on in vivo and in vitro experimental evidence, outline the 
clinical findings, and highlight the possible roles of MMPs in MM, as well as future 
prospects.
2. Crucial roles of MMPs in mesothelial carcinogenesis
Some MMPs are upregulated and considered mesenchymal markers of epithe-
lial-to-mesenchymal transition (EMT), such as MMP-1, MMP-2, and MMP-9 [20]. 
EMT not only is associated with many physiological processes, such as embryonic 
development, but also plays a vital role in pathological processes, including cancer 
cell invasion and migration [21–23]. During EMT, epithelial cells lose their pheno-
type and acquire a mesenchymal phenotype, including the loss of cell polarity and 
cell adhesion in cell-cell and cell-basement membrane interactions and the acquisi-
tion of ECM degradation ability, which is directly related to MMPs. Currently, 
published studies implicate MMPs as inducers of EMT during MM progression. In 
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addition, MMPs play a mediator role in cellular signaling pathways controlled by 
growth factors and cytokines [17, 24]. Here, we describe these two main roles of 
MMPs in MM carcinogenesis. Moreover, we propose possible mechanisms involving 
MMPs, as shown in Figure 1.
2.1 EMT inducer
MMP-1 is an interstitial collagenase that specifically targets the degradation of 
collagen types I–III [25]. Schelch et al. reported that in malignant pleural mesothe-
lioma (MPM) cells in vitro, fibroblast growth factor 2(FGF2) and epidermal growth 
factor (EGF) may induce EMT via mitogen-activated protein kinase kinase (MEK)/
MMP-1 signaling [26]. The experimental results indicated that MMP-1 inhibition 
by the pan-MMP inhibitor GM6001 or transfection with siRNAs targeting MMP-1 
could prevent FGF2-induced cell scattering and invasion in the M38K cell line  
(a biphasic MPM cell line) [26]. In MPM tissue specimens, higher MMP-1 expres-
sion was observed in the sarcomatoid compartment than in the epithelioid 
compartment. Normal pleura were weakly positive for MMP-1 [26]. These results 
suggest that MMP-1 causally contributes to sarcomatoid morphology and increases 
cell invasiveness during EMT.
MMP-2, also named gelatinase A, is expressed by almost all cell types, and 
its classical substrates are denatured collagen (gelatin) and basement membrane 
[25, 27]. Indeed, MMP-2 acts as a cancer-associated EMT inducer or modulator 
in a number of tumors, such as breast cancer [16, 28], hepatocellular carcinoma 
[29], prostate cancer [30], ovarian cancer [31], oral squamous cell carcinoma [32], 
and MM [33]. Regarding MM, MMP-2 secretion from human normal mesothelial 
MeT-5A cells increased upon treatment with chrysotile or transforming growth 
factor-β (TGF-β) [33], and EMT was induced. This in vitro experimental result of 
increased MMP-2 secretion by cells exposed to chrysotile asbestos suggests changes 
in the surrounding microenvironment that render the ECM more amenable to 
degradation and invasion [33, 34]. Of course, the underlying mechanism of MMP-
2-induced EMT in MM development requires further study.
MMP-9 is a type IV collagenase also known as gelatinase B [35] that has a similar 
ability to cleave gelatin as MMP-2. MMP-9 has been recognized as an EMT media-
tor in cancer progression and appears to be a potential therapeutic target [35–37]. 
Figure 1. 
Schematic representation of MMP-involved mechanisms in MM carcinogenesis. See detail in text. MM, 
malignant mesothelioma; EMT, epithelial-to-mesenchymal transition; ECM, extracellular matrix.
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Elevated MMP-9 levels were observed in a 3D microtumor model of patient-derived 
mesothelioma cells, consistent with the elevated MMP-9 levels in patient breast 
tumors compared to healthy mammary glands [38]. Moreover, MMP-9 secreted into 
conditioned media by large microtumors induced a migratory phenotype in nonmi-
gratory small microtumors, and blocking MMP-9 with GM6001 effectively abolished 
the collective migration of mesothelioma microtumors [38]. These findings imply 
that a self-regulated positive feedback loop involving MMP-9 is established during 
tumor progression and migration [38]. Additionally, the invasion of H2052 (meso-
thelioma cell line) and JP5 cells (primary mesothelioma cell line) into a 3D collagen 
matrix induced by gremlin-1 (a protein antagonist of bone morphogenetic proteins) 
was significantly alleviated by GM6001 and BB2516 (broad-spectrum MMP inhibi-
tors) [39]. Interestingly, in our previous study, we found that serum MMP-2 and 
MMP-9 levels were correlated with each other in both healthy control and MM groups 
in a Han cohort from Eastern China [40]. Nevertheless, there were no significant 
differences in MMP-2/MMP-9 levels between the healthy control and MM groups.
2.2 Signaling pathway mediator
Various growth factors, cytokines, and miRNAs engage specific cellular signal-
ing pathways, such as the MEK and extracellular signal-regulated kinase (ERK) 
signaling pathways, to regulate MMP expression levels to degrade the ECM, and 
MMPs then contribute to the release of tumor-related factors, such as vascular 
endothelial growth factor and TGF-β, from the ECM [17, 24].
MMP-1 expression showed an increasing trend in MM cell lines from no treat-
ment to treatment with FGF2 and EGF and a pronounced decrease upon treatment 
with selumetinib (MEK inhibitor), suggesting that the growth factors FGF2 and 
EGF regulate MMP-1 expression via the MEK signaling pathway in MM [26]. TGF-
β, another important growth factor that regulates cell growth and differentiation, 
affects MMP-2 expression in MeT-5A [33] and JL-1 cells [39]. Moreover, growth 
hormone-releasing hormone (GHRH) antagonists (MIA-602 and MIA-690) equally 
blunted MMP-2 and MMP-9 mRNA levels in both REN and MSTO-211H cells (MM 
cell lines), indirectly indicating that MMP-2/MMP-9 expression is induced by 
GHRH [41], as well as by adenosine diphosphate in ZL55 cells (an epithelioid MM 
cell line), via the nuclear factor kappa-B, protein kinase B, and ERK1/2 signaling 
pathways [42]. Interestingly, microtumor treated with GM6001 showed reduced 
pERK/ERK ratios and ERK activation [38]. Notably, miR-591 targets MMP-2 
expression, and overexpression of miR-591 inhibited MMP-2 levels in MPM cells 
[43]. These experimental results show that MMP expression is regulated by various 
factors via multiple signaling pathways and that MMPs interact with such inducers 
and signaling pathways in MM carcinogenesis.
3. Potential roles of MMPs as biomarkers for MM
3.1 Pathological markers
To date, MM is still difficult to diagnose in early stages due to our limited knowl-
edge of its molecular pathogenesis. Indeed, pathological examination techniques 
to diagnose MM and distinguish MM from other diseases must be improved [44]. 
However, more molecular markers are required to distinguish benign from malig-
nant mesothelial disease or other tumors. In addition, effective pathologic predictors 
of prognosis and therapeutic response are urgently needed. Since MMPs are involved 
in tumor pathogenesis, some MMPs may be potential pathological markers.
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In general, MMP expression and activation are very low and tightly regulated 
during normal tissue homeostasis. MMP production and activation are rapidly 
induced during active tissue remodeling and in pathological conditions such as 
cancer [37]. MMP-7 and MMP-14 are potential diagnostic and prognostic biomark-
ers of mesothelioma, respectively. MMP-7 is a highly specific negative biomarker 
to distinguish MM from other high-grade serous carcinomas with 100% specificity 
and moderate sensitivity, but it cannot distinguish mesothelial cells from reac-
tive mesothelial cells in serous effusion due to uniformly negative expression of 
MMP-7 in reactive mesothelial cells [45]. It is intriguing that MMP-14 is a potential 
biomarker for the differential diagnosis of MPM and reactive mesothelial hyperpla-
sia (MH). A group from Italy found that MMP-14 expression is markedly increased 
in MPM patient specimens compared with MH specimens based on polymerase 
chain reaction array and immunohistochemistry analyses [46]. MMP-14 levels have 
been reported to be elevated in all tissue samples from MM patients compared to 
those from normal individuals, but more evidence is needed to substantiate MMP-
14 as a diagnostic biomarker for MM [47]. MMP-14 expression has prognostic value 
for MM. Clinically high MMP-14 expression in MM patients is significantly cor-
related with poor prognosis [47].
3.2 Genetic biomarkers
Although most mesotheliomas are attributable to asbestos exposure, genetic 
factors are also important causes of carcinogenesis. Gene mutations influence the 
prognosis of MM. For example, heritable mutations in BRCA1-associated protein-1 
(BAP1), a tumor suppressor gene, may predispose individuals to asbestos-related 
MM [48, 49]. Moreover, Baumann et al. reported that mesothelioma patients with 
germline BAP1 mutations have a seven-fold improvement in long-term survival [50].
More recently, some MMP single-nucleotide polymorphisms (SNPs) have 
been found to have potential as genetic biomarkers for MM. For instance, Štrbac 
et al. reported that patients carrying a polymorphic MMP-9 rs2250889 allele 
had a negative outcome, with a shorter time to progression (TTP) (6.07 vs. 
10.03 months, HR = 2.45, 95% CI = 1.45–4.14, p = 0.001) and worse overall survival 
(OS) (9.23 vs. 19.2 months, HR = 2.39, 95% CI = 1.37–4.18, p = 0.002) than those 
with the reference allele [51]. However, patients harboring at least one polymor-
phic MMP-9 rs20544 allele had a positive outcome, with a longer TTP (10.93 vs. 
9.40 months, HR = 0.57, 95% CI = 0.38–0.86, p = 0.007) and improved OS (20.67 
vs. 13.50 months, HR = 0.56, 95% CI = 0.37–0.85, p = 0.007) [51]. These research-
ers also found that the MMP-2 rs243865 polymorphism plays a protective role in 
MM; carriers of this polymorphism have a decreased risk for MM (OR = 0.66, 95% 
CI = 0.44–1.00, p = 0.050) [52]. Interestingly, the decreased risk for MM is more 
pronounced in people exposed to asbestos [52]. These findings provide insight into 
some MMP SNPs that are considered genetic biomarkers, indicate the prognosis of 
MM patients, and predict susceptibility to MM. In the future, appropriate genetic 
counseling and clinical management should be considered for MM patients who are 
carriers of MMP-2/MMP-9 susceptibility SNPs.
4. Conclusion
In this chapter, we provide an overview of recent findings on MMP function 
in MM and the mechanisms by which MMPs may induce both phenotypic and 
genotypic alterations that facilitate MM progression and invasion. Accumulating 
evidence indicates that tumor-associated MMPs can stimulate processes associated 
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with EMT, a developmental event that is activated in MM cells during invasion and 
metastasis. Meanwhile, future investigations on extracellular targets and intracel-
lular signaling pathways through which MMPs can induce EMT of MM cells will 
provide insight into novel therapeutic targets. We also describe possible roles of 
MMPs as pathological markers or genetic biomarkers in MM. Certainly, the under-
lying mechanisms of secreted MMPs, including their function and circulation, are 
complex in MM and remain to be elucidated in the future.
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